

PEER-REVIEW REPORT

Name of journal: World Journal of Gastrointestinal Surgery

Manuscript NO: 61568

Title: GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASMS - A
CLINICAL SNAPSHOT

Reviewer's code: 03738819

Position: Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: China

Author's Country/Territory: United Kingdom

Manuscript submission date: 2020-12-11

Reviewer chosen by: Ya-Juan Ma

Reviewer accepted review: 2021-01-02 12:12

Reviewer performed review: 2021-01-04 07:51

Review time: 1 Day and 19 Hours

Scientific quality	<input type="checkbox"/> Grade A: Excellent <input type="checkbox"/> Grade B: Very good <input checked="" type="checkbox"/> Grade C: Good <input type="checkbox"/> Grade D: Fair <input type="checkbox"/> Grade E: Do not publish
Language quality	<input type="checkbox"/> Grade A: Priority publishing <input checked="" type="checkbox"/> Grade B: Minor language polishing <input type="checkbox"/> Grade C: A great deal of language polishing <input type="checkbox"/> Grade D: Rejection
Conclusion	<input type="checkbox"/> Accept (High priority) <input checked="" type="checkbox"/> Accept (General priority) <input type="checkbox"/> Minor revision <input type="checkbox"/> Major revision <input type="checkbox"/> Rejection
Re-review	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No
Peer-reviewer statements	Peer-Review: <input checked="" type="checkbox"/> Anonymous <input type="checkbox"/> Onymous Conflicts-of-Interest: <input type="checkbox"/> Yes <input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

The review by Cornelius J Fernandez et al., aimed to describe the research situation of gastroenteropancreatic neuroendocrine neoplasms from multiple levels. Overall, it contains up-to-date information, but it seems that the authors overfly the details within the different paragraphs. Nonetheless, there are several minor and major issues: - The first line of Table I could be used to describe the entries in each column in Table I. - It would be helpful to add the references in Table II where the data are reported in the columns. - The data content in this paper is lack of references, such as "MEN1 is associated with non-functional pNENs in 80-100%.....and somatostatinomas in 1%." - The NCT number can be supplemented where some new clinical trials are involved, such as "Bevacizumab is undergoing trials..... or progressive NETs." - It is suggested that the content related to molecular mutation characteristics of NENs should be supplemented, especially where it comes to molecular targeted therapy. - In terms of treatment strategy, especially when it comes to surgical strategy, if the latest guidelines are quoted, please put forward the name and version of the guidelines.